Tag: <span>Empagliflozin</span>

Home / Empagliflozin
Post

Empagliflozin offers lasting cardiorenal benefit in CKD patients

by Elana Gotkine Empagliflozin continues to offer cardiorenal benefits for up to 12 months after discontinuation among patients with chronic kidney disease at risk for progression, according to a study published online Oct. 25 in the New England Journal of Medicine to coincide with Kidney Week, the annual meeting of the American Society of Nephrology, held from...

Post

Empagliflozin may decrease risk of kidney stones in people with diabetes

THE ENDOCRINE SOCIETY The diabetes drug empagliflozin may decrease the risk of kidney stones in patients with type 2 diabetes, according to a new study presented Sunday, June 12 at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga. Diabetes is a well-known risk factor for kidney stones. Empagliflozin (Jardiance) is an SGLT2 inhibitor....